These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis. Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464 [TBL] [Abstract][Full Text] [Related]
47. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Doepfner KT; Spertini O; Arcaro A Leukemia; 2007 Sep; 21(9):1921-30. PubMed ID: 17581609 [TBL] [Abstract][Full Text] [Related]
48. AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway. Shemesh II; Rozen-Zvi B; Kalechman Y; Gafter U; Sredni B PLoS One; 2014; 9(12):e114287. PubMed ID: 25474550 [TBL] [Abstract][Full Text] [Related]
49. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia. Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658 [TBL] [Abstract][Full Text] [Related]
50. Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. Li X; Chen F; Zhu Q; Ding B; Zhong Q; Huang K; Jiang X; Wang Z; Yin C; Zhu Y; Li Z; Meng F Oncotarget; 2016 May; 7(22):33004-15. PubMed ID: 27105509 [TBL] [Abstract][Full Text] [Related]
51. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Kalich-Philosoph L; Roness H; Carmely A; Fishel-Bartal M; Ligumsky H; Paglin S; Wolf I; Kanety H; Sredni B; Meirow D Sci Transl Med; 2013 May; 5(185):185ra62. PubMed ID: 23677591 [TBL] [Abstract][Full Text] [Related]
55. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200 [TBL] [Abstract][Full Text] [Related]
56. SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model. Täger M; Horn S; Latuske E; Ehm P; Schaks M; Nalaskowski M; Fehse B; Fiedler W; Stocking C; Wellbrock J; Jücker M Gene Ther; 2017 Nov; 24(11):749-753. PubMed ID: 29143813 [TBL] [Abstract][Full Text] [Related]
57. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Herschbein L; Liesveld JL Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026 [TBL] [Abstract][Full Text] [Related]
58. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Kalechman Y; Longo DL; Catane R; Shani A; Albeck M; Sredni B Int J Cancer; 2000 Apr; 86(2):281-8. PubMed ID: 10738258 [TBL] [Abstract][Full Text] [Related]
59. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
60. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia. Yiau SK; Lee C; Mohd Tohit ER; Chang KM; Abdullah M J Recept Signal Transduct Res; 2019 Jun; 39(3):276-282. PubMed ID: 31509041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]